Are you finding it easier to get authorization for reimbursement and approval of PCSK9 inhibitors now that prices have come down and we have seen clear outcome benefits in both major trials?

Are you finding it easier to get authorization for reimbursement and approval of PCSK9 inhibitors now that prices have come down and we have seen clear outcome benefits in both major trials?

Are you finding it easier to get authorization for reimbursement and approval of PCSK9 inhibitors now that prices have come down and we have seen clear outcome benefits in both major trials?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Matthew Roe, MD

Matthew Roe, MD

Professor of Medicine Duke Clinical Research Institute Duke University School of Medicine Durham, NC